arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Autolus Therapeutics plc

AUTL

$1.31 ▼ -0.07 (-5.07%) at close

11 Visible periods

31 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Autolus Therapeutics plc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $348.6M

Dividend Yield —

Revenue Growth 644.9% ↗

Op. Margin -358.9%

ROIC -152.9% ↘

FCF / Share $-1.14 ↘

Trailing P/E —

Price / Book 2.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

11-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$75.39M

↑ +644.9% —

Net Income Profit after all expenses

$-287.53M

↓ -30.3% —

FCF / Share Free cash flow per share

$-1.14

↓ -27.1% —

Long-Term Debt Long-term obligations

$0.00

↓ -100.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability

Returns ↓

Financial Health ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Sep 30, 2017 20-F ↗	FY 2016 Sep 30, 2016 20-F ↗	FY 2015 Sep 30, 2015 20-F ↗
Revenue Growth YoY (%)	644.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+7962%)	496.0% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+6100%)	—	—	—	—	106.7% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1234%)	-16.9% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-311%)	39.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+396%)	—	—
EPS Growth YoY (%)	-25.6% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	28.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	23.6% Good → Good Stable Year-over-year change in earnings per share Optimal: > 10%	20.3% Good Good Year-over-year change in earnings per share Optimal: > 10%	28.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-30.3% Weak ↓ Weak Declining Year-over-year change in net income	-5.9% Weak ↑ Weak Improving Year-over-year change in net income	-40.0% Weak ↓ Weak Declining Year-over-year change in net income	-4.7% Weak ↑ Weak Improving Year-over-year change in net income	-0.0% Weak ↑ Weak Improving Year-over-year change in net income	-14.7% Weak ↑ Weak Improving Year-over-year change in net income	-176.8% Weak ↓ Weak Declining Year-over-year change in net income	-126.9% Weak Weak Year-over-year change in net income	-57.2% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-27.1% Weak ↓ Weak Declining Year-over-year change in free cash flow	0.6% Caution ↓ Caution Declining Year-over-year change in free cash flow	30.6% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	26.3% Excellent Excellent Year-over-year change in free cash flow	31.6% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—
Revenue CAGR 3Y (%)	—	—	—	—	—	—	33.9% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	—	28.3% Excellent Excellent Compound annual revenue growth over 5 years	3.8% Caution Caution Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Sep 30, 2017 20-F ↗	FY 2016 Sep 30, 2016 20-F ↗	FY 2015 Sep 30, 2015 20-F ↗
Operating Margin (%) (%)	-358.9% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2492%)	—	—	—	—	—	—	—	—	—	—
Effective Tax Rate (%) (%)	-0.7% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.7% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	14.5% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	10.9% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	14.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	15.6% Good Good Actual taxes paid relative to pre-tax income Optimal: 15-25%	12.4% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	-381.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3278%)	—	—	—	—	—	—	—	—	—	—
FCF Margin (%) (%)	-401.4% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	—	—	—	—
FCF / Net Income (x)	1.05x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.03x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Sep 30, 2017 20-F ↗	FY 2016 Sep 30, 2016 20-F ↗	FY 2015 Sep 30, 2015 20-F ↗
Return on Invested Capital (%)	-152.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-56.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-161.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-89.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-45.0% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-68.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-51.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-19.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-45.9% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-30.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-47.9% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-54.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-38.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-57.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-48.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-22.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—
Return on Common Equity (%) (%)	-161.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1176%)	-51.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-444%)	-186.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1346%)	-92.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-716%)	-45.4% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-402%)	-67.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-551%)	-48.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-424%)	-17.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-217%)	-13.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-192%)	-40.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-373%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Sep 30, 2017 20-F ↗	FY 2016 Sep 30, 2016 20-F ↗	FY 2015 Sep 30, 2015 20-F ↗
Debt to Equity (x)	—	—	—	—	—	—	0.00x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.01x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-99%)	—	—
Interest Coverage (x)	-7.38x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-25.98x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-3.99x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-16.10x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-127.65x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	-95.16x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—
Net Debt (USD)	$-104.13M	$-227.38M	$-239.57M	$-163.05M	$-310.34M	—	$0.00	$285.00K	$763.00K	—	—
Debt / EBITDA (x)	—	—	—	—	—	—	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.01x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Sep 30, 2017 20-F ↗	FY 2016 Sep 30, 2016 20-F ↗	FY 2015 Sep 30, 2015 20-F ↗
Revenue per Share (USD)	$0.28	$0.04	$0.01	—	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-1.08	$-0.86	$-1.20	$-1.57	$-1.97	$-2.76	—	—	—	—	—
Free Cash Flow per Share (USD)	$-1.14	$-0.89	$-0.90	$-1.30	$-1.76	$-2.57	—	—	—	—	—
Book Value per Share (USD)	$0.67	$1.67	$0.64	$1.70	$4.35	$4.07	—	—	—	—	—
Tangible Book Value per Share (USD)	$0.67	$1.67	$0.64	$1.70	$4.35	$4.07	—	—	—	—	—
Basic Weighted Avg Shares (shares)	266.14M	255.16M	173.94M	94.99M	72.08M	51.56M	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Sep 30, 2017 20-F ↗	FY 2016 Sep 30, 2016 20-F ↗	FY 2015 Sep 30, 2015 20-F ↗
Working Capital (USD)	$362.48M	$600.19M	$230.56M	$173.49M	$280.62M	$163.35M	$224.27M	$211.89M	$137.45M	—	—
LT Debt (USD)	—	—	—	—	—	—	$0.00	$285.00K	$763.00K	—	—
Total Equity (USD)	$178.13M	$427.32M	$111.47M	$161.15M	$313.32M	$210.03M	$254.84M	$255.47M	$142.60M	$30.69M	$10.50M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Sep 30, 2017 20-F ↗	FY 2016 Sep 30, 2016 20-F ↗	FY 2015 Sep 30, 2015 20-F ↗
Sales/Revenue/Turnover (USD)	$75.39M	$10.12M	$1.70M	—	—	—	$2.91M	$1.41M	$1.69M	$1.21M	—
Depreciation Expense (USD)	$8.30M	$7.55M	$6.57M	$7.42M	$8.46M	$5.66M	$4.61M	$1.71M	$1.01M	$478.00K	—
Net Income, GAAP (USD)	$-287.53M	$-220.66M	$-208.38M	$-148.84M	$-142.10M	$-142.09M	$-123.85M	$-44.75M	$-19.73M	$-12.55M	—
Operating Cash Flow (USD)	$-283.57M	$-206.27M	$-145.59M	$-112.31M	$-117.86M	$-117.76M	$-101.48M	$-31.54M	$-16.36M	$-9.85M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 11 years · 31 quarters

Autolus Therapeutics plc

Analytical Summary

11-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare AUTL with peers